Abstract | BACKGROUND: METHODS: Treatment included: Thiotepa 300 mg/m(2) on days -8, -7, and -6; topotecan 2 mg/m(2) on days -8, -7, -6, -5, and -4; and carboplatin approximately 500 mg/m(2) (Calvert formula-area under the curve = 7) on days -5, -4, and -3. Stem cell rescue was on day 0. RESULTS: Age at study entry ranged from 2.5 to 20 years old (median age 8.7 years). Five had medulloblastoma (MB), four had high grade glioma (HGG), and one had trilateral retinoblastoma/ pineoblastoma (tRB/PB). Prior treatment for all patients included surgery and chemotherapy (1-7 regimens, median 2). Nine patients received radiotherapy; one patient did not receive radiotherapy pre-study. Three patients had residual disease at the time of transplant. There were two toxic deaths. Four patients are event-free survivors at a median of 6 years (range 2.8-7.6 years) after treatment including 2/5 MB patients, 1/4 HGG patients, and the tRB/PB patient. Four of the seven patients with no evidence of disease/ minimal residual disease status at the time of stem cell rescue are long-term survivors versus 1/3 with measurable disease. CONCLUSION:
|
Authors | Stephen W Gilheeney, Yasmin Khakoo, Mark Souweidane, Suzanne Wolden, Farid Boulad, Ira J Dunkel |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 54
Issue 4
Pg. 591-5
(Apr 2010)
ISSN: 1545-5017 [Electronic] United States |
PMID | 19998470
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Topotecan
- Thiotepa
- Carboplatin
|
Topics |
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carboplatin
(administration & dosage, adverse effects)
- Central Nervous System Neoplasms
(drug therapy)
- Child
- Child, Preschool
- Combined Modality Therapy
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Male
- Neoplasm Recurrence, Local
(drug therapy)
- Prognosis
- Thiotepa
(administration & dosage, adverse effects)
- Topotecan
(administration & dosage, adverse effects)
- Young Adult
|